Responses
Regular Abstracts – Part 2
Checkpoint Blockade Therapy
579-A Targeting the NANOG-CRY1 axis sensitizes immunotherapy-refractory tumors and enhances efficacy of T cell-based immunotherapy by reinvigorating the anti-tumor immunity cycle
Compose a Response to This Article
Other responses
No responses have been published for this article.
